Home Cart Sign in  
Chemical Structure| 911417-62-4 Chemical Structure| 911417-62-4

Structure of 911417-62-4

Chemical Structure| 911417-62-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 911417-62-4 ]

CAS No. :911417-62-4
Formula : C23H17N5O3
M.W : 411.42
SMILES Code : O=C(O)COC1=CC=CC(C2=NC(NC3=CC4=C(NN=C4)C=C3)=C5C=CC=CC5=N2)=C1

Safety of [ 911417-62-4 ]

Application In Synthesis of [ 911417-62-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 911417-62-4 ]

[ 911417-62-4 ] Synthesis Path-Downstream   1~1

  • 1
  • [ 911417-62-4 ]
  • [ 33024-60-1 ]
  • 2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2-yl)phenoxy)-N-(tetrahydro-2H-pyran-4-yl)acetamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
46% A suspension of 2-(3-(4-(lH-indazol-5-ylamino)quinazolin-2- yl)phenoxy)acetic acid (70 mg, 0.14 mmol), PyBOP.(R). (40 mg, 0.077 mmol), DIEA (24 muL, 0.14 mmol) in dry CH2Cl2 : DMF (2 : 0.1 mL) was stirred at RT for 15 minutes. To this solution of activated acid was added <strong>[33024-60-1]tetrahydro-2H-pyran-4-amine hydrochloride</strong> (13 mg, 0.091 mmol). After 30 minutes, 1.0 equivalent of DIEA and 0.55 equivalents of PyBOP.(R). were added. After stirring the solution for 15 minutes, 0.65 equivalents of tetrahydro-2H- pyran-4-amine hydrochloride were added and the mixture was stirred for an additional 30 minutes. The solvent was removed in vacuo and the crude product was purified using prep HPLC (15-40_90 mins) to afford 2-(3-(4-(lH-indazol-5-ylamino)quinazolin-2- yl)phenoxy)-N-(tetrahydro-2H-pyran-4-yl)acetamide. (32 mg, 0.065 mmol, 46 percent)
46% A suspension of 2-(3-(4-( 1H-indazol-5-ylamino)quinazolin-2- yl)phenoxy)acetiotac acid (70 mg, 0 14 mmol), PyBOP* (40 mg, 0 077 mmol), DItA (24 muL, 0 14 mmol) in dry CH2CI5 DMF (2 0 1 ml.) was stirred at RT for 15 minutes To this solution of activated acid was added <strong>[33024-60-1]tetrahydro-2H-pyran-4-amine hydrochloride</strong> ( 13 mg. 0.091 nimol). After 30 minutes, 1.0 equivalent of DlEA and 0.55 equivalents of PyBOP* were added. After stirring the solution for 15 minutes, 0.65 equivalents of tetrahydro-2H- pyran-4-amine hydrochloride were added and the mixture was stirred for an additional 30 minutes. The solvent was removed //; vacuo and the caide product was purified using prep HPLC (15-40_90 mins) to afford 2-(3-(4-(1H-indazol-5-ylamino)quinazolin-2- yl)phenochiy)-N-(tetrahydro-2H-pyran-4-yl)acetamide. (32 mg, 0.065 mmol, 46 percent).
46% [0250] A suspension of 2-(3-(4-(lH-indazol~5-ylamino)quinazolin-2- yl)phenoxy)acetic acid (70 mg, 0.14 mmol), PyBOP.(R). (40 mg, 0.077 mmol), DIEA (24 muL, 0.14 mmol) in dry CH2Cl2 : DMF (2 : 0.1 mL) was stirred at RT for 15 minutes. To this solution of activated acid was added <strong>[33024-60-1]tetrahydro-2H-pyran-4-amine hydrochloride</strong> (13 mg, EPO <DP n="129"/>0.091 mmol). After 30 minutes, 1.0 equivalent of DlEA and 0.55 equivalents of PyBOP.(R). were added. After stirring the solution for 15 minutes, 0.65 equivalents of tetrahydro~2H- pyran-4-amine hydrochloride were added and the mixture was stirred for an additional 30 minutes. The solvent was removed in vacuo and the crude product was purified using prep HPLC (15-40_90 mins) to afford 2-(3-(4-(lH-mdazol-5-ylamino)qumazolin-2- yl)phenoxy)-N-(tetrahydro-2H-pyran-4-yl)acetamide. (32 mg, 0.065 mmol, 46 percent)
 

Historical Records